EditForce
company
About
EditForce develops drugs and seeds by using nucleic acid manipulation technologies.
- Fukuoka,Fukuoka,Japan
- 11 - 50
- https://www.editforce.co.jp/
Details
- Last Funding Type
- Series Unknown
- Last Funding Money Raised
- ¥800M
- Industries
- Biotechnology,Medical,Nursing and Residential Care
- Founded date
- May 15, 2015
- Number Of Employee
- 11 - 50
- Operating Status
- Active
- Legal Name
- EditForce Inc., Edit Force Co., Ltd.
EditForce develops drugs and seeds by using nucleic acid (DNA/RNA) manipulation technologies.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
3
¥1.84B
EditForce has raised a total of
¥1.84B
in funding over 2 rounds. Their latest funding was raised on
May 26, 2021 from a Series Unknown round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| May 26, 2021 | Series Unknown | ¥800M | 4 |
Newton Biocapital
|
— | Detail |
| Mar 1, 2019 | Series B | ¥870M | 6 | — | — | Detail |
| Feb 3, 2016 | Seed | ¥175M | 2 |
UTEC - The University of Tokyo Edge Capital Partners
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
2
8
EditForce is funded by 8 investors.
Newton Biocapital
and Global Brain Corporation
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Newton Biocapital
|
Yes | Series Unknown |
Global Brain Corporation
|
— | Series Unknown |
ITOCHU Technology Ventures
|
— | Series Unknown |
|
UTEC - The University of Tokyo Edge Capital Partners
|
— | Series Unknown |
Japan Science and Technology Agency
|
— | Series B |
K4 Ventures
|
— | Series B |
QB Capital
|
— | Series B |
KISCO
|
— | Seed |
Employee Profiles
Number of Employee Profiles
10
EditForce has 10 current employee profiles, including
Board member Tomotaka Goji
Board member
Board member
Executive
Board member
Employee
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
